gsk6097608
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 25, 2020 (NCT04446351)
Timeline
Indications
Mechanism of action
- T-cell surface protein tactileINHIBITOR
CD96 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5315022 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06062420 | Phase 2 | Oct 4, 2023 | GlaxoSmithKline, iTeos Therapeutics |
| NCT06926673 | Phase 2 | Dec 23, 2021 | GlaxoSmithKline |
| NCT04446351 | Phase 1 | Jun 25, 2020 | 23andMe, Inc., GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 2 | 2020 |
| 23andMe, Inc. | For profit | 1 | 0 | 1 | 2020 |
| iTeos Therapeutics | For profit | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1